Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine

Journal of the National Cancer Institute

Volumn 96, Issue 8, 2004, Pages 604-615

  Goldie, Sue J ^a   Kohli, Michele ^b   Grima, Daniel ^b   Weinstein, Milton C ^a,b   Wright, Thomas C ^c   Xavier Bosch, F ^d   Franco, Eduardo ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b i3 Global   (Canada)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE; PAPILLOMA VIRUS VACCINE;

ADULT; AGE; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MARKETING; FEMALE; FREQUENCY ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNE DEFICIENCY; LIFE EXPECTANCY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS; AGED; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; INCIDENCE; MASS SCREENING; MIDDLE AGED; MORTALITY; PAPILLOMA VIRUS; STANDARD; UNITED STATES; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGED; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 2342613014     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh104     Document Type: Article

References (115)

1. Bosch FX, Lorincz A, Munoz N, Meijer CC, Shah KV. The causal relationship between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1973-1994. National Cancer Institute, Bethesda (MD). Available at: http://seer.cancer.gov/csr/1973_1994/. [Last accessed: March 4, 2004.]
3. Miller AB. Failures of cervical cancer screening. Am J Public Health 1995;85:795.
4. Follen M, Richards-Kortum R. Emerging technologies and cervical cancer. J Natl Cancer Inst 2000;92:363-5.
5. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Human papillomaviruses. Lyon (France): IARC; 1995.
6. Schiffman M. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1995;87:1345-7.
7. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506-11.
8. Walboomers J, Jacobs M, Manos M, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
9. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
10. Koutsky LA, Ault K, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
11. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papilllomavirus vaccines. J Natl Cancer Inst Monogr 2003;(31):111-6.
12. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 2:131-47.
13. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, et al. Modeling for health care and other policy decisions: uses, roles and validity. Value Health 2001;4:348-61.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
15. Goldie SJ, Grima D, Kohli M, Weinstein MC, Wright TC, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV 16/18 vaccine. Int J Cancer 2003;106:896-904.
16. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-90.
17. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999;130:97-107.
18. Goldie SJ, Kuhn L, Denny L, Pollack, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
19. Myers E, McCrory D, Nanda K, Matchar D. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
20. Mandelblatt J, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-81.
21. Wright TC, Ferenczy AF, Kurman RJ. Chapter 7: Precancerous lesions of the cervix. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. New York (NY): Springer-Verlag; 2002.
22. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999;65:243-9.
23. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.
24. Ferenczy A, Franco EL. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002;3:11-6.
25. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesions development in young females. JAMA 2001;285: 2995-3002.
26. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human paillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
27. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341: 1633-8.
28. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
29. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rosendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
30. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508-17.
31. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica. 1999;6:223-33.
32. Arias E. United States Life Tables, 2000. National vital statistics reports. Vol 51. No. 3. Hyattsville (MD): National Center for Health Statistics; 2002.
33. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. Available at: http://www.cdc.gov/brfss/. [Last accessed; March 4, 2004.]
34. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al., editors. SEER Cancer Statistics Review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003. Available at: http:seer.cancer.gov/csr/ 1975_2000. [Last accessed: March 4, 2004.]
35. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 1999;281:347-53.
36. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002;94:193-204.
37. Hutchinson ML, Berger BM, Farber FL. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity. Am J Manag Care 2000;6:766-80.
38. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3: i-iv, 1-196.
39. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996;65:768-73.
40. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP - Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
41. Solomon D, Schiffman M, Tarrone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
42. Franco E, Villa L, Sobrinho J, Prado JM, Rousseau MC, Desy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
43. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
44. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
45. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
46. Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, Brown W, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998;25:243-50.
47. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7.
48. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-41.
49. Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
50. McCrory DC, Matchar DB, Bastain L, Datta S, Hasselblad V, Hickey J, et al. Evaluation of cervical cytology. Evidence Report/Technology Assessment No. 5. AHCPR Publication No. 99-E010. Rockville (MD): Agency for Health Care Policy and Research; February 1999.
51. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 1999;354:20-5.
52. Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-7.
53. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364-8.
54. Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9.
55. Ho G, Burk R, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
56. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Bickmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
57. Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JM, Kenemans P, Helmerhorst TJ. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000;107:600-4.
58. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
59. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92(4 Pt 2):727-35.
60. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
61. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 1992;79:675-82.
62. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9.
63. Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. Obstet Gynecol 1998;92:745-52.
64. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999;103:539-45.
65. Fonn S, Bloch B, Mabina. M, Carpenter S, Cronje H, Maise C, et al. Prevalence of pre-cancerous lesions and cervical cancer in South Africa - a multicentre study. S Afr Med J 2002;92:148-56.
66. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
67. Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA, et al. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. JAMA 1994;271:1181-8.
68. Liaw K, Glas AG, Manos MM, Greer CE, Scott DR, Sherman M, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
69. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
70. Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intraepithelial neoplasia. Int J Cancer 1998;78:281-5.
71. Schiff M, Becker TM, Masuk M, van Asselt-King L, Wheeler CM, Altobelli KK, et al. Risk factors for cervical intraepithelial neoplasia in southwestern American Indian women. Am J Epidemiol 2000;152:716-26.
72. Pretorius R, Semrad N, Watring W, Fotheringham N. Presentation of cervical cancer. Gynecol Oncol 1991;42:48-53.
73. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon (France): IARC Press; 2001.
74. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997;71:159-65.
75. Fidler HK, Boyes DA, Worth AJ. Cervical cancer detection in British Columbia: a progress report. J Obstet Gynaecol Br Commonw 1968;75: 392-404.
76. Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol 2000;23:19-22.
77. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia [published erratum appears in Gynecol Oncol 2002;84:355]. Gynecol Oncol 2001;83:439-44.
78. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. Inclusion of HPV-testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-7.
79. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
80. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000;89:529-34.
81. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
82. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
83. Diaz-Rosario LA, Kabawat SE. Performance of a fluid-based, thin-layer Papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England. Arch Pathol Lab Med 1999;123:817-21.
84. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-9.
85. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999;87:48-55.
86. Nanda K, McCrory DC, Myers ER, Bastain LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
87. Sulik SM, Kroeger K, Schultz JK, Brown JL, Becker LA, Grant WD. Are fluid-based cytologies superior to the conventional Papanicolaou test? A systematic review. J Fam Pract 2001;50:1040-6.
88. Stratton K, Durch J, Lawrence R, eds. Vaccines for the 21st century a tool for decisionmaking. Washington (DC): National Academy Press; 2000.
89. Krahn M, Guasparini R, Sherman M, Detsky A. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health 1998;88:1638-44.
90. U.S. Bureau of Labor Statistics. Statistical Abstract of the United States. Washington (DQ: U.S. Government Printing Office; 2001; USDL 96-186.
91. Helms LJ, Melnikow J. Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care 1999;37:652-61.
92. Centers for Medicare and Medicaid Services. National Physician Fee Schedule Relative Value File. Medicare Physician Fee Schedule. Available at: http://www.cms.hhs.gov/physicians/pfs/#2002. [Last accessed: March 8, 2004.]
93. 2001 Clinical Diagnostic Laboratory Fee Schedule. Public Use File (PUF). Available at: http://www.cms.hhs.gov/providers/pufdownload/ default.asp/. [Last accessed: March 17, 2004.]
94. Shireman TI, Tsevat J, Goldie SJ. Time costs associated with cervical cancer screening. Intl J Technol Assess Health Care 2001;17:146-52.
95. Statistical Abstract of the United States: Consumer Price Index-All Urban Consumers. Washington (DC): 2001; National Center for Health Statistics. Available at: http://stats.bls.gov/cpi/. [Last accessed: March 17, 2004.]
96. Wolfson MC. Health-adjusted life expectancy. Health Rep 1996;8:41-6.
97. Gold M, Franks P, McCoy K, Fryback D. Towards consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-92.
98. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 2003;8:s333-45.
99. World Health Organization (WHO). Current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting, Geneva, 16-18 February 1999. Geneva (Switzerland): Department of Vaccines and other Biologicals, WHO, International Agency for Research on Cancer. Available at: http://www.who.int/ vaccine_research/documents/en/hpv1.pdf. [Last accessed: March 4, 2004.]
100. Lehtinen M, Dillner J. Preventative human papillomavirus vaccination. Sex Transm Infect 2002;78:4-6.
101. Lowy DR, Schiller JT. Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta 1999;1423:M1-8.
102. Lehtinen M, Paavonen J. Efficacy of preventative human papillomavirus vaccination. Int J STD & AIDS 2001;12:771-6.
103. Crum C. The beginning of the end for cervical cancer. N Engl J Med 2002;347:1703-4.
104. Schiller JT, Hidesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000;19:67-74.
105. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology 2002;13:631-9.
106. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-48.
107. Kulasingham SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
108. Miller BA, Kolonel LN, Bernstein L, Young JL, Swanson GM, West DW, et al., editors. Racial/ethnic patterns of cancer in the United States 1988-1992. Bethesda (MD): National Institutes of Health; 1998. http://seer. cancer.gov/publications/ethnicity/. [Last accessed: March 17, 2004.]
109. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
110. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
111. Goldie SJ. Public health policy and cost-effectiveness analysis: mathematical modeling of HPV and cervical cancer. J Natl Cancer Inst Monogr 2003;31:102-10.
112. Garnett G, Waddell H. Public health paradoxes and the epidemiology of human papillomavirus vaccination. J Clin Virol 2000;19:101-12.
113. Koopman JS. Modeling infection transmission - the pursuit of complexities that matter. Epidemiology 2002;13:622-4.
114. Halloran ME, Struchiner CJ, Longhini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997;146:789-803.
115. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999;18: 3263-82.